Skip to content

Non-interventional study.

OTHER3 trials

Sponsors

Universitätsklinikum Freiburg, Abteilung Nuklearmedizin, F. HOFFMANN-LA ROCHE LTD, GlaxoSmithKline

Conditions

C75.9Patients diagnosed with locally advanced/metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)- positive tumor mutations should also have received targeted therapy NSCLCPulmonary Disease, Chronic Obstructive

Related Papers